Tango Therapeutics, Inc. - Common Stock (TNGX)

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares of its common stock and pre-funded warrants to purchase up to 1,833,395 shares of its common stock (the “Offering”). The offering price of each share of common stock is $30.00. The offering price of each pre-funded warrant is $29.999, which represents the per share offering price for the common stock less the $0.001 per share exercise price for such pre-funded warrant. The gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering-related expenses, are expected to be approximately $600 million. All of the shares and pre-funded warrants in the Offering are to be sold by Tango. The Offering is expected to close on or about June 11, 2026, subject to customary closing conditions. In addition, Tango has granted the underwriters a 30-day option to purchase up to an additional 3,000,009 shares of common stock at the public offering price, less the underwriting discount.

BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the launch of an underwritten public offering (the “Offering”) of $500 million of its common stock. All shares of common stock to be sold in the Offering will be offered by Tango. Tango also intends to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 of shares of its common stock offered in the Offering under the same terms and conditions. The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed, or the actual size or terms of the Offering.

Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability of clinical benefit 

BOSTON, June 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective June 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 170,000 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.

This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.

Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases.

Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.

This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.

Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.

This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.

First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that effective May 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted (i) a non-qualified stock option to purchase an aggregate of 240,000 shares of its common stock and 40,000 restricted stock units (RSUs) to Matthew Gall, the Company’s Chief Financial Officer and (ii) a non-qualified stock option to purchase an aggregate of 199,650 shares of its common stock and 33,250 RSUs to a new employee, under Tango Therapeutics' 2023 Inducement Plan.

-  Matthew Gall appointed Chief Financial Officer  --  Additional key appointments add expertise in clinical operations, corporate strategy and project leadership  -

This precision oncology developer reported a notable insider sale during a period of robust share price gains.

This clinical-stage biotech focused on targeted cancer therapies reported a notable insider sale.

Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.

Issued on behalf of Oncolytics Biotech Inc.

This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.

This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.

This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.